VA
PTGX icon

Vident Advisory’s Protagonist Therapeutics PTGX Stock Holding History

Vident Advisory’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Buy
4,481
+290
+7% +$25.7K ﹤0.01% 1288
2025
Q4 		$366K Sell
4,191
-879
-17% -$71.9K ﹤0.01% 1303
2025
Q3 		$337K Buy
+5,070
New +$288K ﹤0.01% 1355

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Vident Advisory's PTGX Position: Q1 2026 in Review

Vident Advisory increased its Protagonist Therapeutics (PTGX) stake by 6.9% in Q1 2026, buying an estimated $25.7K and bringing the position to 4,481 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #1288.

Vident Advisory first reported a position in PTGX in Q3 2025 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Vident Advisory held 4,481 shares of Protagonist Therapeutics worth $472K as of Q1 2026.
  • Vident Advisory bought 290 Protagonist Therapeutics shares in Q1 2026, an estimated $25.7K.
  • Protagonist Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1288 holding.
  • Vident Advisory first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.